can tirzepatide cause erectile dysfunction may raise testosterone, improve function Are GLP-1 Drugs Linked to

Unlimited clinician messaging

and Mexico between March and November 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised that cardiovascular risk increases mainly at high doses (2,400 mg daily or more), though this has not been established at standard over-the-counter doses

Crucially, there was reportedly no pharmacovigilance system in place to monitor or respond to adverse drug reactions, despite SAHPRA noting "reports of adverse events, including hospitalisations, linked to the use of these products." All GIP/GLP-1 injectable products found on the site were seized, and iDexis was instructed to initiate a full recall of affected products distributed through healthcare providers, pharmacies, and other channels